Searched for
DRUG PRICING STRATEGY
ITC bulking up with products rich in protein and fibre: Sanjiv Puri“India is also a protein-deficient market. We already have offerings such as high-protein atta, soya chunks and protein shakes, and we will...- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Staggering amounts of fentanyl hit US streets as the DEA watched and took no action, records showDEA agents in New Mexico allegedly allowed hundreds of thousands of fentanyl pills onto streets between 2023-2025, prioritizing larger case...
- Forget AI and EVs: Zerodha’s Nikhil Kamath spots next big billion-dollar opportunity hidden in India’s biggest problemNikhil Kamath water business idea: India's rapid growth in water-intensive sectors like agriculture, nuclear energy, pharmaceuticals, and d...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...
- Dabur India shares in focus after US FDA places drugs from Silvassa plant under import alert. Here’s whyDabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data ...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- US drugs site TrumpRx to list 600 generics as Donald Trump targets lower pricesPresident Donald Trump is expanding access to affordable medicines. The government website TrumpRx.gov will now list over 600 generic drugs...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow TuckerEli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...
Load More
